Successful Completion of Patient Enrolment in INSIGHT-003
Immutep Limited, a dynamic clinical-stage biotechnology company, has reached an important milestone in its INSIGHT-003 trial, designed to evaluate the efficacy of eftilagimod alpha (efti) combined with pembrolizumab and chemotherapy. This multi-centre trial focuses on treating patients with advanced non-small cell lung cancer (NSCLC), having successfully enrolled approximately 50 evaluable patients across several clinical sites in Germany.
Overview of the INSIGHT-003 Trial
The INSIGHT-003 trial represents a significant step forward in lung cancer treatment strategies. As a first-line treatment, this study evaluates the combination therapy of efti with the well-known anti-PD-1 therapy Keytruda (pembrolizumab) and a typical chemotherapy regimen. This unique approach aims to enhance patient outcomes in a population that urgently needs effective treatment options.
Enrolment Metrics and Expectations
Patient enrolment for the INSIGHT-003 trial has commenced under the direction of the prestigious Frankfurt Institute of Clinical Cancer Research IKF. The trial targets advanced or metastatic non-squamous NSCLC patients, indicating a commitment to addressing this pressing health challenge. The future looks promising, with further data updates anticipated beyond 2025.
Impressive Early Results from INSIGHT-003
The INSIGHT-003 trial has already produced some noteworthy findings. Initial data released in mid-November highlight that among 21 patients with a minimum follow-up period of 22 months, the median overall survival achieved was an impressive 32.9 months. Additionally, the results demonstrated a 24-month survival rate of 81.0%. These statistics are considerably more favorable compared to prior studies. For context, a registrational trial assessing a similar chemotherapy regimen indicated a 22.0 month median overall survival with a 24-month survival rate of 45.5%.
What Makes INSIGHT-003 Unique?
INSIGHT-003 stands out not only in its innovative treatment approach but also in its clinical structure. This trial operates as the third arm of the ongoing Phase I INSIGHT trial, under the guidance of Prof. Dr. Salah-Eddin Al-Batran. The study's focus on a triple combination therapy represents Immutep's commitment to exploring new methods for improving survival rates in lung cancer patients.
About Immutep Limited
As a pioneering entity in biotechnology, Immutep Limited specializes in developing LAG-3 immunotherapies for cancer and autoimmune diseases. With a robust portfolio of therapies that stimulate or suppress immune responses, Immutep is dedicated to innovating treatment options for patients. The company's relentless pursuit of advancements in immunotherapy is poised to create substantial benefits for patients and shareholders alike.
Immutep's Vision Moving Forward
Looking ahead, Immutep is determined to leverage its unique expertise in the LAG-3 pathway to enhance treatment outcomes for patients suffering from various conditions. The company's mission extends towards maximizing value for shareholders while prioritizing advancements that benefit patient care.
Frequently Asked Questions
What is the INSIGHT-003 trial about?
The INSIGHT-003 trial is evaluating the efficacy of eftilagimod alpha combined with pembrolizumab and chemotherapy for treating advanced non-small cell lung cancer.
How many patients are involved in the INSIGHT-003 trial?
Approximately 50 evaluable patients are participating in the trial across various clinical sites in Germany.
What were the early results of the INSIGHT-003 trial?
Initial results indicated a median overall survival of 32.9 months and a 24-month overall survival rate of 81.0% among participants with at least 22 months follow-up.
What will happen next in the trial?
Further data updates from the INSIGHT-003 trial are expected in 2025 and beyond, which are crucial for assessing the therapy's long-term effectiveness.
Who is leading the INSIGHT-003 trial?
The trial is led by Prof. Dr. Salah-Eddin Al-Batran and is conducted by the Frankfurt Institute of Clinical Cancer Research IKF, alongside other German centres.
